

ANTIBACTERIAL ACTIVITY AND HUMAN CELL CYTOTOXIC OF COBALT (III) COMPLEXES WITH 1,10-PHENANTHROLINE AND CARBOHYDRATE LIGANDS

JOSÉ PARADA^{1*}, ANA MARÍA ATRIA¹, RICARDO BAGGIO², GUILLERMO WIESE³, SEBASTIÁN LAGOS³, ALEQUIS PAVÓN³, ELIZABETH RIVAS³, LAURA NAVARRO³, GINO CORSINI³

¹Departamento de Química Inorgánica y Analítica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Casilla 233, Santiago, Chile.

²Gerencia de Investigación y Aplicaciones, Centro Atómico Constituyentes, Comisión de Energía Atómica, Buenos Aires, Argentina.

³Laboratorio de Bacteriología Molecular, Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago, Chile.

ABSTRACT

The mononuclear cobalt (III) complex derived from 1,10-phenanthroline with lactose $[\text{Co}(\text{phen})_2\text{lactose}]_2\text{Cl}_2 \cdot 3\text{H}_2\text{O}$ (**1**) has been prepared and its properties have been compared with the sucrose complex $[\text{Co}(\text{phen})_2\text{sucrose}]_2\text{Cl}_2 \cdot 3\text{H}_2\text{O}$ (**2**) and the complex without carbohydrate $[\text{Co}(\text{phen})_2\text{Cl}_2]_2\text{Cl} \cdot 3\text{H}_2\text{O}$ (**3**).

The chemical structure of (**1**) was assigned by ¹H-NMR, IR, CD and UV-Vis spectral data. The antibacterial activity of (**1**) - (**3**) was evaluated by disc-diffusion assays, using Gram-negative and positive bacteria. The minimum inhibitory concentration of the three complexes on the studied bacteria and their cytotoxicity on HEK293 human cells was determined. A colorimetric plate assay was used to distinguish bacteriostatic from bactericidal effect. Finally, the complexes uptake mechanism was evaluated using bacteria with mutated genes that encode for carbohydrate and siderophore receptors. The results indicate that complex (**1**) has an antibacterial activity similar to (**3**), while (**2**) presents a more restricted one. Moreover, all three complexes act by a bacteriostatic effect against bacterial cells and both (**1**) and (**3**) use a siderophore uptake mechanism to enter on bacterial cytoplasm. Cytotoxicity assays show that carbohydrate complexes are not cytotoxic to human cells, in contrast with complex (**3**), which is highly toxic. These results suggest that the use of the lactose ligand would maintain the antibacterial activity and uptake mechanism of the complex at reasonable levels, and would also reduce its toxicity against human cells. Thus, its strategic use would allow a decrease in toxicity of complexes used in eventual studies on eukaryotic systems.

Keywords: Phenanthroline, Cobalt, complexes, Carbohydrate, antibacterial, cytotoxicity.

1. INTRODUCTION

Transition metals and their complexes are of current interest from several point of view, including their use as antimicrobial, antifungal, anticancer, antioxidant, an anti-inflammatory agent, etc. [1-4]. A wide variety of transition metal complexes, including Ag, Au, Cu, Co, Fe, Ir, Pt, Rh and different ligands, have shown antimicrobial properties [5-14]. The biological activity of these compounds is highly dependent on the nature of the metal ions as well as the donor sequence of the intervening ligands (different ligands exhibiting different biological properties [15]).

Regarding this, 1,10-phenanthroline and its derivatives have been extensively used to obtain a diversity of complexes which display a broad range of biological activities, finding application as antitumor, antibacterial and antiviral agents [16-25].

On the other hand, cobalt is one of the most important trace elements for most animal species and humans [26]. Cobalt in inorganic form is a micronutrient for bacteria, algae, and fungi [27]. This element is found on vitamin B12, a coenzyme that plays an important role in various metabolic functions, including the ability to convert proteins, carbohydrates, and fats into energy [28, 29].

Reports on antibacterial properties of cobalt complexes have demonstrated that their antibacterial activity is usually enhanced as compared to that of the free ligand [30]. This seems to be the result of the increasing lipophilicity of the metal upon ligand coordination, which subsequently promotes the permeation through lipid bilayers of the cell membrane, thus blocking the metal-binding sites on the enzymes of microorganisms [31-33].

Considering the increase of bacterial diseases, the synthesis of compounds that prevent bacterial growth, and have a low cytotoxicity is of great interest. In this context, our research group has focused their attention on the synthesis of transition metal mixed complexes that present antimicrobial activity.

In this paper, we report the synthesis of the mononuclear complex $[\text{Co}(\text{phen})_2\text{lactose}]_2\text{Cl}_2 \cdot 3\text{H}_2\text{O}$ (**1**), the evaluation of its antibacterial activity on Gram-negative and positive bacteria, and the cytotoxicity on normal human cells HEK293. The activity is compared to the one presented by mononuclear complexes $[\text{Co}(\text{phen})_2\text{sucrose}]_2\text{Cl}_2 \cdot 3\text{H}_2\text{O}$ (**2**) and $[\text{Co}(\text{phen})_2\text{Cl}_2]_2\text{Cl} \cdot 3\text{H}_2\text{O}$ (**3**) previously synthesized. In addition, the action mechanisms and uptake routes of the three complexes have been explored.

2. EXPERIMENTAL SECTION

2.1. Materials and instruments

All reagents and solvents employed were commercially available and used as received, without further purification.

The cobalt content of the complexes in the solutions, as in the solid compounds was determined by atomic absorption spectroscopy with a Perkin Elmer 1100B spectrophotometer. Absorption spectra were recorded on a Unicam UV3 spectrometer instrument. The circular dichroism (CD) spectra were monitored in a Yobin-Yvon CD 6 spectrometer. Elemental analyses were performed on CE Instruments EA 1108 elemental analyzer.

The infrared spectrum (4000- 600 cm^{-1}) was recorded using a KBr pellet on a Perkin Elmer FT-IR C 97945 IR spectrometer. ¹H-NMR measurements were performed in a DMSO solution with a Bruker DXR 300 spectrometer (300MHz).

2.2 Synthesis of the complexes

Complex (**1**) was prepared using the method reported by Parada *et al.* for the preparation of $[\text{Co}(\text{phen})_2\text{L}]_2^{2+}$ (L=sucrose) (**2**). An aqueous solution of $[\text{Co}(\text{phen})_2\text{Cl}_2]_2\text{Cl}$ (10^{-2} mol/L) was mixed with two fold molar excess lactose and the pH adjusted to 9.0 by addition of NaOH [34]. The precursor complex, $[\text{Co}(\text{phen})_2\text{Cl}_2]_2\text{Cl} \cdot 3\text{H}_2\text{O}$ (**3**) was prepared with a method reported by Ablov [35].

The complexes were separated by chromatography on a Sephadex C25 column and were eluted with 0.1 mol/L NaCl.

The eluate was evaporated to dryness under reduced pressure, followed by extraction with ethanol and methanol, to remove the NaCl. Anal. Calcd for $\text{CoC}_{36}\text{H}_{43}\text{N}_4\text{O}_{14}\text{Cl}_2$: Co, 6.66; C, 48.82; H, 4.86; N, 6.33, Found: Co, 7.15; C, 48.32; H, 4.69; N, 5.87.

2.3. Antimicrobial activity measurements

All the antimicrobial activity assays were performed in triplicate and confirmed by three separate experiments. The antimicrobial activity was investigated against some Gram-positive (*Enterococcus faecalis* ATCC29212, *Bacillus cereus* GCA234 and *Staphylococcus aureus* ATCC25923) and Gram-negative bacteria (*Escherichia coli* ATCC25922, *Escherichia coli* DH5a, *Salmonella enterica* subsp. *enterica* serotype *Enteritidis* ISP/953, *Klebsiella pneumoniae* RyC492).

Bacteria were grown in Müller Hinton agar (Difco), as well as Müller Hinton broth (Difco) for 24 to 48 h at 37 °C in an incubator.

The *in vitro* antibacterial activity of the complexes was tested through paper disc-diffusion method [36], and the minimal inhibitory concentrations (MICs) were determined as the lowest concentrations of drug that inhibits visible bacterial growth [37].

2.4 Antibacterial effect

The *in vitro* antibacterial effect of the complexes was tested using a modified chromogenic plate test assay [38]. *E. coli* HB101, which contains a chromosomal IPTG-inducible β -galactosidase gene, was used for this purpose.

The chromogenic agar plates were prepared as follows: first, an inoculum with the strain was grown overnight in 2 mL of Mueller Hinton media, at 37 °C with shaking. Then, a top agar-incubation mix of 5 mL of 0.8% agar previously melted at 45 °C containing 0.1 mL of the bacterial cell inoculum, 0.01 mL of 1 mmol/L IPTG, and 0.1 mL of X-Gal 50 mg/mL was vortex-mixed and carefully overlaid on Müller Hinton agar plates prepared the day before. Discs containing the appropriate concentration of complex (1), complex (2) or antibiotic (ceftizoxime and chloramphenicol) were deposited on the chromogenic agar plates. The plates were then incubated at 37 °C for 12-24 h. Later, the inhibition zones were visually inspected for color formation along de edges of the discs, and plates were photographed. Only compounds causing cellular lysis, can produce a blue-colored edge at the inhibition zone.

2.5. Growth inhibition test of *E. coli* mutant

To determine the proteins involved in the uptake of complexes into bacteria, growth inhibition plate assays on *E. coli* K12 mutant strain for outer membrane siderophore receptors (*shuA*, *sepA*, *fiu* and *cir*), lactose permease gene (*lacY*) and genes of translocator system (*tonB*, *exbB* and *exbD*) were performed in triplicate and confirmed by three separate experiments. Briefly, an inoculum with *E. coli* K12 mutant strains (HB101, P8, IR20, H1598, VR42, BR158, HE1 or CH03) were grown overnight in 2 mL of Müller Hinton broth, at 37 °C with shaking. Then, a top agar incubation mix containing 5 mL of 0.8% agar previously melted at 45 °C and 0.1 mL of the bacterial cell inoculum was vortex-mixed and carefully overlaid on Müller Hinton agar plates prepared the day before. The discs containing 300 μ g of complexes (1), (2) or (3) were deposited on the agar plates, which were then incubated at 37 °C for 12-24 h, after which the inhibition zones were visually inspected and measured.

2.6 Cytotoxic effect

The cytotoxicity of complexes was tested *in vitro* on human cells using microplate cultures of human kidney embryonic cells (HEK293 cells), grown in DMEM medium plus 10% bovine fetal serum. The number of dead cells was determined by MTT cell proliferation assay after a 24 h incubation period [39]. This method is a colorimetric assay system that measures the reduction of a tetrazolium component (MTT) into an insoluble formazan product by the mitochondria of viable cells.

The amount of color produced is directly proportional to the number of viable cells. The HEK293 cell line was obtained from Dr. Eduardo Karahanian (Biomedical Research Institute, Universidad Autónoma de Chile).

3. RESULTS AND DISCUSSION

3.1 Spectroscopic characterization of $[\text{Co}(\text{phen})_2\text{lactose}]\text{Cl}_2 \cdot 3\text{H}_2\text{O}$ (1)

The IR spectrum of (1) showed the characteristic bands of the 1,10-phenanthroline and lactose ligands. The spectrum shows a broad absorption band at 3352 cm^{-1} that can be associated with $\nu(\text{O-H})$ of lactose, and weak bands at 2990 and 2901 cm^{-1} that can be assigned to C-H stretching vibrations of lactose and phenanthroline, respectively. At the 1584-1428 cm^{-1} region the spectrum shows bands corresponding to $\nu(\text{C}=\text{C}, \text{C}=\text{N})$ of the phenanthroline ligand. Bands between 1377 – 1315 cm^{-1} involve O-H, CH, and CH_2 bending modes of lactose. The band at 1156 cm^{-1} has been assigned to the C-C in-plane bending, and the bands at 1016 and 1003 cm^{-1} have been identified as bands associated with the C-O-C bending. The νH (in-plane) and δH (out-plane) vibration of phenanthroline are located in the 890-668 cm^{-1} region.

In the $^1\text{H-NMR}$ spectrum of the complex (1), we found two groups of well-separated signals. At the 7.1-9.2 ppm region, signals from aromatic hydrogens of the phenanthroline and at 3.2-5.2 ppm region the lactose signals were found. Both signals are in a 1:2 ratio, which agrees with the proposed structure of the complex.

At the anomeric region, the signals belonging to the H-1 of α -glucose (5.12 ppm, $J_{1,2}=3.6\text{Hz}$), the H-1 of β -glucose (4.56 ppm, $J_{1,2}=7.9\text{Hz}$) and the H-1 of β -galactose (4.56 ppm, $J_{1,2}=7.9\text{Hz}$) can be distinguished (Table 1).

At the 3.2-3.8 ppm region there are overlapping signals and a triplet of the H bonded to the non-anomeric carbons of the lactose.

Table 1: ^1H chemical shifts (δ , ppm) and coupling constant $J_{1,2}$ (Hz) of $[\text{Co}(\text{phen})_2\text{lactose}]^{2+}$ complex (1) and lactose in D_2O .

δ , ppm	H-1(β -gal)	H-1(α -glu)	H-1(β -glu)
Complex (1)	4.35	5.12	4.56
Lactose	4.34	5.11	4.55
$J_{1,2}$ (Hz)			
Complex (1)	7.8	3.6	7.9
Lactose	7.7	3.6	8

gal= galactose; glu=glucose

An absorption band at 271 nm is seen in the UV spectrum of (1) (Fig 1). The band is associated with p transitions of the 1,10-phenanthroline ligands. In this region, the CD spectrum presents two bands of opposite sign, which appears at 267 (+) and 281 (-) nm. The sign sequence is related to the Δ configuration of the chelate rings (excitonic effect) [40].

The complex showed a second positive CD signal as a shoulder in the UV region (295 nm), related to the $\pi \rightarrow \pi^*$ transition along the short axis of phenanthroline rings.

In the visible region, complex (1) exhibited an absorption band at 523 nm corresponding to the $^1\text{A}_{1g} \rightarrow ^1\text{T}_{1g}$ transition. In the CD spectra, two signals (+) and (-) can be detected, which are correlated with the Δ configuration [41]. The CD spectra also showed a third signal (-) at 360 nm than can be assigned to the $^1\text{T}_{2g}$ state in octahedral symmetry.

The UV-VIS absorption and CD spectra of (1) are consistent with those reported earlier for $[\text{Co}(\text{phen})_2\text{L}]\text{Cl}_2$, where L=sucrose or maltose [42, 43].




Figure 1: Absorption and circular dichroism (CD) spectra of $[\text{Co}(\text{phen})_2\text{lactose}]^{2+}$ complex (1).

3.2. Antimicrobial activity of the three cobalt complexes

The *in vitro* antibacterial activity of complexes (1), (2) and (3) was evaluated against representative Gram-positive and Gram-negative bacteria. Discs with ceftizoxime (ZOX) were used as a control. The results of antibacterial activity and minimum inhibitory concentration (MIC) are reported in Tables 2 and 3, respectively.

The results of this study revealed that (1) and (2) were active against all tested bacteria with minimum inhibitory concentration ranging from 40-70 µg/mL and 50-80 µg/mL respectively, while complex (3) was active against Gram-negative organisms with minimum inhibitory concentration ranging from 40-

80 µg/mL, and inactive against the Gram-positive bacteria, showing moderate activity against *Staphylococcus aureus*.

The three complexes showed less antibacterial activity than ceftizoxime (ZOX), but, surprisingly, both complexes (1) and (2) exhibited antibacterial activity against *Enterococcus faecalis* and *Bacillus cereus*, bacteria which are resistant to ceftizoxime.

Disc-diffusion assays showed a similar antibacterial activity of (1) and (3) against Gram-negative bacteria (Table 2), as shown by the MIC's results presented in Table 3.

Table 2. Qualitative antibacterial activity of the tested complexes.

Bacteria	Growth inhibition zone (mm)*			
	[Co(phen) ₂ lactose] ²⁺ (1)	[Co(phen) ₂ sucrose] ²⁺ (2)	[Co(phen) ₂ Cl ₂] ⁺ (3)	ZOX
<i>Escherichia coli</i> ATCC25922	18.0±0.1	9.3±0.6	19.8±0.8	31.0±0.4
<i>Escherichia coli</i> DH5a	18.2±0.8	8.7±0.6	19.5±0.5	31.0±0.5
<i>Salmonella</i> Enteritidis ISP/953	14.3±0.2	14.5±0.9	10.3±1.5	32.0±0.6
<i>Klebsiella pneumoniae</i> RyC492	14.7±0.2	11.5±1.0	15.0±0.1	31.0±0.5
<i>Enterococcus faecalis</i> ATCC29212	12.2±0.5	9.2±0.6	R	R
<i>Bacillus cereus</i> GCA234	14.8±0.9	14.4±0.3	R	R
<i>Staphylococcus aureus</i> ATCC25923	11.3±0.9	12.8±0.5	7.3±0.6	34.1±0.7

* Material used: disc with 300 µg of compound. Number of assays = 3. ZOX: ceftizoxime (disc with 30 µg). R is resistant

Table 3. Minimum inhibitory concentration (MIC) of complexes tested.

Bacteria	MIC (µg/mL)*		
	[Co(phen) ₂ lactose] ²⁺ (1)	[Co(phen) ₂ sucrose] ²⁺ (2)	[Co(phen) ₂ Cl ₂] ⁺ (3)
<i>Escherichia coli</i> ATCC25922	40	80	40
<i>Salmonella</i> Enteritidis ISP/953	50	50	80
<i>Klebsiella pneumoniae</i> RyC492	50	60	50
<i>Enterococcus faecalis</i> ATCC 29212	70	80	>500
<i>Bacillus cereus</i> GCA234	50	50	>500
<i>Staphylococcus aureus</i> ATCC25923	60	60	90

*Number of assays = 3.

A cobalt (III) complex reported by Arunachalam *et al.* cis-[Co(phen)₂(C₁₄H₂₉NH₂)Cl] (ClO₄)₂·3H₂O has a similar antibacterial activity against *S. aureus*, *Bacillus subtilis*, and *E. coli*, with growth inhibition zones in a range of 15-11 mm. The authors indicate that the high antibacterial activity can be related to the hydrophobic character of the compound [44].

Another example is the cobalt (III) complex with 2,2-bipyridine [Co(PZAH)(bipy)₂](ClO₄)₂, where PZAH₂=pyrazinamide, reported by Chiniforoshan *et al.* [45]. This complex generates growth inhibition zones of 24.5 and 22.3 mm of diameter against *Bacillus* and *E. coli* respectively.

Moreover, cobalt (II) complexes with antibacterial activity and MIC values similar to those of complex (1) have been reported. For example, [Co(valp)₂(phen)H₂O] complex (Valp= sodium valproate, phen= 1,10-phenanthroline) has MIC values of 50 µg/mL and 30 µg/mL against *S. aureus* and *E. coli* respectively [7].

3.3 Antibacterial-action mode and uptake mechanism of the three cobalt complexes.

To distinguish the antimicrobial-action mode of the complexes studied, a colorimetric plate assay method was used [46, 47], with β-galactosidase chosen as an appropriate marker of cellular lysis. If lysis occurs, the enzyme is released outside the bacterium and detected on the plate.

When the enzyme reaches the agar medium, it hydrolyzes 5-bromo-4-

chloro-3-indolyl-β-D-galactoside (X-Gal), a chromogenic compound included in the agar. After overnight incubation, X-Gal forms a blue circle staining the edge of the inhibition zone produced by the antibiotic application. It is perhaps pertinent to emphasize that only those compounds causing cellular lysis or membrane damage do produce a blue-colored edge at the inhibition zone (bactericide effect).

The assay showed that (1), (2) and (3) present bacteriostatic activity against bacterial cells since they do not produce a blue circle staining the edge of the inhibition zone (Fig. 2). In these assays, ceftizoxime and chloramphenicol were used as bactericidal and bacteriostatic control agents, respectively. The results indicate that the three complexes studied have their target on the inside of the bacterial cell.

Considering that (1), (2), and (3) have a bacteriostatic effect on the bacterial cell, two possible routes for internalization or uptake of complexes were explored. The first one implies a specific sugar receptor for carbohydrate transport into *E. coli*, lacY protein [48]. The second route analyzed corresponds to a siderophore uptake pathway, that includes an outer-membrane receptor and translocation system TonB (TonB/ ExbB/ ExbD proteins) [49]. For these assays, *E. coli* mutated for lacY protein and siderophore receptors were used.

From the results in Table 3, it can be seen that the activity of complex (1) on *E. coli* HB101 (*lacY* mutant) decreases slightly as compared with the

activity it presents against *E. coli* DH5 α . The growth inhibition zone reduces from 18.2 to 16.8 mm. On the other hand, complexes (2) and (3) maintain their antibacterial activity. These results suggest that (1) presents further internalization routes to the bacterium in addition to *lacY*. Complexes (2) and (3), instead, do not use this route of entry.

When the activity of *E. coli* strains with mutated genes for siderophore receptors (P8, IR20, H1598, VR42) are analyzed, the results show that the antibacterial activity of complexes (1) and (3) decreases markedly as compared to the activity against *E. coli* DH5 α , used as a control. This could indicate that complexes (1) and (3) might use as the main gateway to the bacteria the outer-

membrane proteins FhuA, FepA, Cir and Fiu. In the case of complex (2), no change is observed in the activity against the mutated bacteria, suggesting that this complex uses different routes to enter into the bacteria.

A similar situation occurs when using mutated *E. coli* in the translocation system (BR158, HE1, and CH03). Complexes (1) and (3) present a decreased antibacterial activity unlike complex (2) which maintains it unaltered. These results indicate that complexes (1) and (3) use the translocation system TonB / ExbB / EXBD, in order to cross from the periplasm to the cytoplasm of the cell. Complex (2) instead would use a different route of entry.




Figure 2. Plate assay showing a bacteriostatic or bacteriolytic effect for complexes (1), (2) and (3) against Gram-negative bacterium *Escherichia coli* HB101. Materials used in the assay: a disc with 400 μg of the analyzed complex, and discs of ceftizoxime (30 $\mu\text{g}/\text{disc}$) and chloramphenicol (30 $\mu\text{g}/\text{disc}$), which were used as bacteriostatic and bacteriolytic control respectively.

Table 3. Growth inhibition test of mutant *E. coli* strains by complexes tested.

<i>E. coli</i> strain	Mutated gene	Function of mutated protein	Growth inhibition zone (mm)*		
			[Co(phen) ₂ lactose] ²⁺ (1)	[Co(phen) ₂ sucrose] ²⁺ (2)	[Co(phen) ₂ Cl ₂] ⁺ (3)
DH5α	-	-	18.2±0.8	8.7±0.6	19.5±0.5
HB101	<i>lacY</i>	Lactose importer	16.8±0.3	8.7±0.6	19.2±0.8
P8	<i>fhuA</i>	Siderophore out membrane receptor	6.0±0.1	8.2±0.9	6.0±0.1
IR20	<i>fepA</i>	Siderophore out membrane receptor	6.0±0.1	7.7±0.1	6.0±0.1
H1598	<i>fiu</i>	Siderophore out membrane receptor	6.0±0.1	8.7±0.1	6.0±0.1
VR42	<i>cirA</i>	Siderophore out membrane receptor	6.0±0.1	8.5±0.1	6.0±0.1
BR158	<i>tonB</i>	Principal component of inner membrane uptake	6.0±0.1	8.5±0.3	6.0±0.1
HE1	<i>exbB</i>	Accessory component of TonB system	6.0±0.1	9.1±0.1	6.0±0.1
CH03	<i>exbD</i>	Accessory component of TonB system.	6.0±0.1	8.3±0.9	6.0±0.1

*Number of assays = 3.




Figure 3. The *in vitro* cytotoxicity effect of complexes (1), (2) and (3) against human cell (HEK293 cell). The graphic A (gray bar), corresponds to cell viability of a HEK293 cell line incubated with [Co(phen)₂lactose]²⁺ (1) during 24 h. The graphic B (white bar with horizontal lines), corresponds to cell viability of a HEK293 cell line incubated with [Co(phen)₂sucrose]²⁺ (2), during 24 h. The graphic C (white bar with vertical lines), corresponds to cell viability of a HEK293 cell line incubated with [Co(phen)₂Cl₂]⁺ (3) during 24 h. Non-statistical differences were detected ($p > 0.05$) for graphics A and B, while statistical differences were detected ($p < 0.05$) for graphic C.

3.4 Cytotoxicity effect against human cell

In order to evaluate the ability of compounds to damage eukaryotic cells, the *in vitro* cytotoxic effect of these complexes was tested with human kidney embryonic cells (HEK293 cell) (Fig. 3).

The data obtained from the MTT assay showed that complex (1) is not toxic to human cells in the tested concentrations range. Similarly, complex (2) did not show cytotoxicity in human cells (no statistical differences were detected ($p > 0.05$) in the range of tested concentrations).

In contrast, the complex (3) is cytotoxic in all the range of studied concentrations (Fig. 3C).

These results suggest that the presence of carbohydrates as ligands in the complexes reduces cytotoxicity against human kidney embryonic cells, which is consistent with the results previously obtained for complexes with maltose or arabinose [43].

It is worth noting that when the cytotoxicity of new compounds is evaluated, the corresponding studies are usually performed on tumor cell lines. Since the final aim of this research is to find compounds to inhibit growth or even destroy the bacteria with no harm to healthy cells, the alternative of using ligands or complexes with little or no cytotoxicity on eukaryotic cells is interesting.

4. CONCLUSIONS

We synthesized a new cobalt (III) complex with phenanthroline and lactose (1). Based on its optical properties, a formula $[\text{Co}(\text{phen})_2\text{lactose}]\text{Cl}_2 \cdot 3\text{H}_2\text{O}$ and an absolute delta configuration have been assigned to the complex (1).

The *in vitro* assays showed that the complexes (1), (2) and (3) exhibited moderate antibacterial activity, with bacteriostatic effect over the studied bacteria.

The presence of carbohydrate ligands in the complexes (1) and (2) improves the antibacterial properties over Gram positive in contrast with complex (3).

Assays using mutant *E. coli* strains demonstrate that TonB-dependent siderophore uptake system is involved in uptake and transport of the complexes (1) and (3) into the bacterial cell.

Furthermore, the MTT assays using human cell treated with complexes (1), (2) and (3) showed that the presence of carbohydrate ligands decreases the cytotoxic effect over the eukaryotic cell of the metal complexes tested.

REFERENCES

- 1.- B. S. Sekhon, *J. Pharm. Educ. Res.* **2**, 1, (2011)
- 2.- A. K. Ghosh, M. Mitra, A. Fathima, H. Yadav, A.R. Choudhury, B.U. Nair, R. Ghosh, *Polyhedron* **107**, 1, (2016)
- 3.- A. Alomar, A. Landreau, M. Allain, G. Bouet, G. Larcher, *J. Inorg. Biochem.* **126**, 76, (2013)
- 4.- K. D. Mjos and C. Orvig, *Chem. Rev.* **114**, 4540, (2014)
- 5.- S. V. Kumar, S. Scottwell, E. Waugh, C. J. McAdam, L. R. Hanton, H. J. L. Brooks, J. D. Crowley, *Inorg. Chem.* **55**, 9767, (2016)
- 6.- M. Salehi, M. Hasanzadeh, *Inorg. Chim. Acta* **426**, 6, (2015)
- 7.- L. Tabrizi, P. McArdle, M. Ektefan, H. Chiniforoshan, *Inorg. Chim. Acta* **439**, 138, (2016)
- 8.- M. Salehi, M. Amirasr, S. Meghdadi, K. Mereiter, H.R. Bijanzadeh, A. Khaleghian, *Polyhedron* **81**, 90, (2014)
- 9.- P. Fernandes, I. Sousa, L. Cunha-Silva, M. Ferreira, B. de Castro, E.F. Pereira, M.J. Feio, P. Gameiro, *J. Inorg. Biochem.* **131**, 21, (2014)
- 10.- D.U. Miodragovic, G.A. Bogdanovic, Z.M. Miodragovic, M.D. Radulovic, S.B. Novakovic, G.N. Kaludjerovic, H. Kozlowski, *J. Inorg. Biochem.* **100**, 1568, (2006)
- 11.- K. Nomiya, A. Yoshizawa, K. Tsukagoshi, N.C. Kasuga, S. Hirakawa, J. Watanabe, *J. Inorg. Biochem.* **98**, 46, (2004)
- 12.- D. Bandyopadhyay, M. Layek, M. Fleck, R. Saha, C. Rizzoli, *Inorg. Chim. Acta* **461**, 174, (2017)
- 13.- H. Keypour, M. Mahmoudabadi, A. Shoostari, M. Bayat, M. Ghassemzadeh, L. Hosseinzadeh, F. Mohsenzadeh, K. Harms, *Polyhedron* **129**, 189, (2017)
- 14.- R. Sethi, M. Ahuja, *Int. Pharm. Tech. Res.* **9** (1), 35, (2016)
- 15.- C. X. Zhang, S.J. Lippard, *Curr. Opin. Chem. Biol.* **7**, 481, (2003)
- 16.- T.W. Failes, T.W. Hambley, *Dalton Trans.* 1895, (2006)
- 17.- B. Coyle, K. Kavanagh, M. McCann, M. Devereux, M. Geraghty, *Biometals* **16**, 321, (2003)
- 18.- H. Gopinathan, N. Komathi, M.N. Arumugham, *Inorg. Chim. Acta* **416**, 93, (2014)
- 19.- P. Heffeter, M.A. Jakupec, W. Körner, S. Wild, N.G. von Keyserlingk, L. Elbing, H. Zorbas, A. Korynevska, S. Knasumüller, H. Sutterlüty, M. Micksche, B.K. Keppler, W. Berger, *Biochem. Pharm.* **71**, 426, (2006)
- 20.- P. Gameiro, C. Rodrigues, T. Baptista, I. Sousa, B. de Castro, *Int. J. Pharm.* **334**, 129, (2007)
- 21.- A. T. Colak, P. Oztopcu-Vatan, F. Colak, D. Akduman, S. Kabadere, R. Uyar, *J. Trace Elem. Med. Biol.* **27**, 295, (2013)
- 22.- M. A. Zoroddu, S. Zanetti, R. Pogni, R. Basosi, *J. Inorg. Biochem.* **63** (4), 291, (1996)
- 23.- S. S. Hindo, M. Frezza, D. Tomco, M. J. Heeg, L. Hryhorczuk, B. R. McGarvey, Q. P. Dou, C.N. Verani, *Eur. J. Med. Chem.* **44**, 4353, (2009)
- 24.- P. F. Liguori, A. Valentini, M. Palma, A. Bellusci, M. Palma, A. Bellusci, S. Bernardini, M. Ghedini, M. L. Panno, C. Pettinari, F. Marchetti, A. Crispini, D. Pucci, *Dalton Trans.* **39**, 4205, (2010)
- 25.- M. Geraghty, V. Sheridan, M. McCann, M. Devereux, V. McKee, *Polyhedron* **18**, 2931, (1999)
- 26.- L.R. McDowell, *Vitamins in Animal and Human Nutrition*. Iowa State University Press, Ames, 2000
- 27.- G.T Taylor, C.W. Sullivan, *Limnol. Oceanogr.* **53** (5), 1862, (2008)
- 28.- J. M. Pratt, *Inorganic chemistry of vitamin B12*. Academic Press, New York, 1972
- 29.- E. C. Hatchikian, *Biochem. Biophys. Res. Commun.* **103**, 521, (1981)
- 30.- E.L. Chang, C. Simmers, D. A. Knight, *Pharmaceuticals* **3**, 1711, (2010)
- 31.- R. S. Kumar, P. Paul, A. Riyasdeen, G. Wagnières, H. van den Bergh, M. A. Akbarsha, S. Arunachalam, *Colloids and Surfaces B: Biointerfaces*, **86**, 35, (2011)
- 32.- B. Zarranz, A. Jaso, I. Aldana, A. Monge, *Bioorg. Med. Chem.* **11**, 2149, (2003)
- 33.- J. J. Iraraj, A.G. Motten, C.F. Chignell, *Chem. Res. Toxicol.* **16**, 164, (2003)
- 34.- a) J. Parada, S. Bunel, C. Ibarra, G. Larrazábal, E. Moraga, *Carbohydr. Res.* **329**, 195, (2000). b) J. Parada, G. Larrazábal, *Polyhedron* **23**, 1341, (2004)
- 35.- A.V. Ablov, *Russ. J. Inorg. Chem.* **6**, 157, (1961)
- 36.- K. L. Kwaniewska, *Bull. Environ. Contam. Toxicol.* **27**, 289, (1981)
- 37.- National Committee for Clinical Laboratory Standards: Methods for Dilution. Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA, 2000.
- 38.- G. Mardones, A. Venegas, *J. Microbiol. Meth.* **40**, 199, (2000)
- 39.- S. Maher, M. McClean, *Biochem. Pharmacol.* **71**, 1289, (2006)
- 40.- a) C. J. Hawkins, *Absolute Configuration of Metal Complexes*, Wiley, New York, 1971.
b) K. Nakanishi, N. R. W. Berova, Woody (Eds.), *Circular Dichroism, Principles and Applications*, VCH, Cambridge, 1994.
- 41.- I. Tinoco, *Adv. Chem. Phys.* **4**, 113, (1962). b) F.S. Richardson, *J. Chem. Phys.* **54**, 2453, (1971)
- 42.- J. Parada, S. Bunel, C. Ibarra, G. Larrazábal, E. Moraga, N.G. Gillitt, C. A. Bunton, *Carbohydr. Res.* **333**, 185, (2001)
- 43.- J. Parada, A.M. Atria, G. Weiss, E. Rivas, G. Corsini, *J. Chil. Chem. Soc.* **59**, 2636, (2014)
- 44.- R. S. Kumar, S. Arunachalam, *Biophys. Chem.* **136**, 136, (2008)
- 45.- H. Chiniforoshan, Z. Sadeghian Radani, L. Tabrizi, H. Tavakol, M. R. Sabzalian, G. Mohammadnezhad, H. Görls, W. Plass, *J. Mol. Struct.* **1081**, 237, (2015)
- 46.- P. Cortés-Cortés, A.M. Atria, M. Contreras, O. Peña, K. Fernandez, G. Corsini, *J. Chil. Chem. Soc.* **53**, 1527, (2008)
- 47.- A.M. Atria, P. Cortés-Cortés, M.T. Garland, R. Baggio, K. Morales, M. Soto, G. Corsini, *J. Chil. Chem. Soc.* **56**, 786, (2011)
- 48.- M. H. Saier, *Mol. Microbiol.* **35**, 699, (2000)
- 49.- K. Schauer, B. Gouget, M. Carrière, A. Labigne, H. De Reuse, *Mol. Microbiol.* **63**, 1054, (2007).